<?xml version="1.0" encoding="UTF-8"?>
<SubmissionLabel drug="CARDIZEM_LA">
  <Text>
    <Section id="S1" name="adverse reactions">    ADVERSE REACTIONS

  Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded from these studies.



 In the hypertension study, the following table presents adverse reactions more common on diltiazem than on placebo (but excluding events with no plausible relationship to treatment), as reported in placebo-controlled hypertension trials in patients receiving a diltiazem hydrochloride extended-release formulation (once-a-day dosing) up to 540 mg.




                                            Placebo          Diltiazem hydrochloride extended-release   
 Adverse Reactions (MedDRA Term)        n= 120# pts (%)      120-360 mgn= 501# pts (%)  540 mgn= 123# pts (%)    
  
 Oedema lower limb                           4 (3)                   24 (5)                  10 (8)           
 Sinus congestion                            0 (0)                   2 (1)                   2 (2)            
 Rash NOS                                    0 (0)                   3 (1)                   2 (2)            
          In the angina study, the adverse event profile of CARDIZEM LA was consistent with what has been previously described for CARDIZEM LA and other formulations of diltiazem HCl. The most frequent adverse effects experienced by CARDIZEM LA-treated patients were edema lower-limb (6.8%), dizziness (6.4%), fatigue (4.8%), bradycardia (3.6%), first-degree atrioventricular block (3.2%), and cough (2%).
 

 In clinical trials of other diltiazem formulations involving over 3200 patients, the most common events (i.e. greater than 1%) were edema (4.6%), headache (4.6%), dizziness (3.5%), asthenia (2.6%), first-degree AV block (2.4%), bradycardia (1.7%), flushing (1.4%), nausea (1.4%) and rash (1.2%).



 In addition, the following events have been reported infrequently (less than 2%) in hypertension trials with other diltiazem products:



   Cardiovascular:  Angina, arrhythmia, AV block (second- or third-degree), bundle branch block, congestive heart failure, ECG abnormalities, hypotension, palpitations, syncope, tachycardia, ventricular extrasystoles.



   Nervous System:  Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor.



   Gastrointestinal:  Anorexia, constipation, diarrhea, dry mouth, dysgeusia, mild elevations of SGOT, SGPT, LDH, and alkaline phosphatase (see hepatic warnings), nausea, thirst, vomiting, weight increase.



   Dermatological:  Petechiae, photosensitivity, pruritus.



   Other:  Albuminuria, allergic reaction, amblyopia, asthenia, CPK increase, crystalluria, dyspnea, ecchymosis, edema, epistaxis, eye irritation, headache, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, neck rigidity, nocturia, osteoarticular pain, pain, polyuria, rhinitis, sexual difficulties, gynecomastia.



 The following postmarketing events have been reported infrequently in patients receiving diltiazem: allergic reactions, alopecia, angioedema (including facial or periorbital edema), asystole, erythema multiforme (including Stevens-Johnson syndrome, toxic epidermal necrolysis), exfoliative dermatitis, extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, increased bleeding time, leukopenia, purpura, retinopathy, and thrombocytopenia. In addition, events such as myocardial infarction have been observed which are not readily distinguishable from the natural history of the disease in these patients. A number of well-documented cases of generalized rash, some characterized as leukocytoclastic vasculitis, have been reported. However, a definitive cause and effect relationship between these events and diltiazem therapy is yet to be established.
</Section>
    <Section id="S2" name="precautions">    PRECAUTIONS



    General  



  Diltiazem hydrochloride is extensively metabolized by the liver and excreted by the kidneys and in bile. As with any drug given over prolonged periods, laboratory parameters of renal and hepatic function should be monitored at regular intervals. The drug should be used with caution in patients with impaired renal or hepatic function.



 In subacute and chronic dog and rat studies designed to produce toxicity, high doses of diltiazem were associated with hepatic damage. In special subacute hepatic studies, oral doses of 125 mg/kg and higher in rats were associated with histological changes in the liver, which were reversible when the drug was discontinued. In dogs, doses of 20 mg/kg were also associated with hepatic changes; however, these changes were reversible with continued dosing.



 Dermatological events (see  ADVERSE REACTIONS  section) may be transient and may disappear despite continued use of diltiazem. However, skin eruptions progressing to erythema multiforme and/or exfoliative dermatitis have also been infrequently reported. Should a dermatologic reaction persist, the drug should be discontinued.



    



   Drug Interactions.  Due to the potential for additive effects, caution and careful titration are warranted in patients receiving diltiazem concomitantly with other agents known to affect cardiac contractility and/or conduction (see  WARNINGS  ). Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with diltiazem (see  WARNINGS  ).



 As with all drugs, care should be exercised when treating patients with multiple medications. Diltiazem is both a substrate and an inhibitor of the cytochrome P-450 3A4 enzyme system. Other drugs that are specific substrates, inhibitors, or inducers of this enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem. Patients taking other drugs that are substrates of CYP450, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels.



    



   Beta-Blockers.  Controlled and uncontrolled domestic studies suggest that concomitant use of diltiazem and beta-blockers is usually well tolerated, but available data are not sufficient to predict the effects of concomitant treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities.



 Administration of diltiazem concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%. In vitro  , propranolol appears to be displaced from its binding sites by diltiazem. If combination therapy is initiated or withdrawn in conjunction with propranolol, an adjustment in the propranolol dose may be warranted (see  WARNINGS  ).



    



   Buspirone.  In nine healthy subjects, diltiazem significantly increased the mean buspirone AUC 5.5 fold and Cmax4.1 fold compared to placebo. The T1/2 and Tmaxof buspirone were not significantly affected by diltiazem. Enhanced effects and increased toxicity of buspirone may be possible during concomitant administration with diltiazem. Subsequent dose adjustments may be necessary during co-administration, and should be based on clinical assessment.



    



   Cimetidine.  A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and area-under-the-curve (53%) after a 1-week course of cimetidine at 1200 mg per day and a single dose of diltiazem 60 mg. Ranitidine produced smaller, nonsignificant increases. The effect may be mediated by cimetidine's known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem. Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine. An adjustment in the diltiazem dose may be warranted.



    



   Digitalis.  Administration of diltiazem with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%. Another investigator found no increase in digoxin levels in 12 patients with coronary artery disease. Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem therapy to avoid possible over- or under-digitalization (see  WARNINGS  ).



    



   Anesthetics.  The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers. When used concomitantly, anesthetics and calcium blockers should be titrated carefully.



    



   Benzodiazepines.  Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3- to 4-fold and the Cmaxby 2-fold, compared to placebo. The elimination half-life of midazolam and triazolam also increase (1.5 to 2.5 fold) during coadministration with diltiazem. These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sedation) of both midazolam and triazolam.



    



   Cyclosporine.  A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients. In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem. If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.



 The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated.



    



   Carbamazepine.  Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.



    



   Lovastatin.  In a ten-subject study, coadministration of diltiazem (120 mg bid diltiazem SR) with lovastatin resulted in a 3 - 4 times increase in mean lovastatin AUC and Cmaxversus lovastatin alone; no change in pravastatin AUC and Cmaxwas observed during diltiazem coadministration. Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.



    



   Quinidine.  Diltiazem significantly increases the AUC(0-&gt;âˆž)of quinidine by 51%, T1/2 by 36%, and decreases its CLoralby 33%. Monitoring for quinidine adverse effects may be warranted and the dose adjusted accordingly.



    



   Rifampin.  Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels. Coadministration of diltiazem with rifampin or any known CYP 3A4 inducer should be avoided when possible, and alternative therapy considered.



     Carcinogenesis, Mutagenesis, Impairment of Fertility.  



  A 24-month study in rats at oral dosage levels of up to 100 mg/kg/day, and a 21-month study in mice at oral dosage levels of up to 30 mg/kg/day showed no evidence of carcinogenicity. There was also no mutagenic response or in mammalian cell assays or in vitro in bacteria. No evidence of impaired fertility was observed in a study performed in male and female rats at oral dosages of up to 100 mg/kg/day.



    



    Pregnancy.    Category C. Reproduction studies have been conducted in mice, rats, and rabbits. Administration of doses ranging from 4 to 6 times (depending on species) the upper limit of the optimum dosage range in clinical trials (480 mg q.d. or 8 mg/kg q.d. for a 60 kg patient) resulted in embryo and fetal lethality. These studies revealed, in one species or another, a propensity to cause fetal abnormalities of the skeleton, heart, retina, and tongue. Also observed were reductions in early individual pup weights, pup survival, as well as prolonged delivery times and an increased incidence of stillbirths.



 There are no well-controlled studies in pregnant women; therefore, use diltiazem in pregnant women only if the potential benefit justifies the potential risk to the fetus.



    



    Nursing Mothers.    Diltiazem is excreted in human milk. One report suggests that concentrations in breast milk may approximate serum levels. If use of diltiazem is deemed essential, an alternative method of infant feeding should be instituted.



    



    Pediatric Use.    Safety and effectiveness in pediatric patients have not been established.



    



    Geriatric Use.    Clinical studies of diltiazem did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
</Section>
    <Section id="S3" name="warnings">    WARNINGS



   



    *  1.   Cardiac Conduction. Diltiazem prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second- or third-degree AV block (13 of 3290 patients or 0.40%). Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem (see  ADVERSE REACTIONS  section). 
       
 

    *  2.   Congestive Heart Failure. Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dp/dt). An acute study of oral diltiazem in patients with impaired ventricular function (ejection fraction 24% +/- 6%) showed improvement in indices of ventricular function without significant decrease in contractile function (dp/dt). Worsening of congestive heart failure has been reported in patients with preexisting impairment of ventricular function. Experience with the use of diltiazem in combination with beta-blockers in patients with impaired ventricular function is limited. Caution should be exercised when using this combination. 
       
 

    *  3.   Hypotension. Decreases in blood pressure associated with diltiazem therapy may occasionally result in symptomatic hypotension. 
       
 

    *  4.   Acute Hepatic Injury. Mild elevations of transaminases with and without concomitant elevation in alkaline phosphatase and bilirubin have been observed in clinical studies. Such elevations were usually transient and frequently resolved even with continued diltiazem treatment. In rare instances, significant elevations in enzymes such as alkaline phosphatase, LDH, SGOT, SGPT, and other phenomena consistent with acute hepatic injury have been noted. These reactions tended to occur early after therapy initiation (1 to 8 weeks) and have been reversible upon discontinuation of drug therapy. The relationship to diltiazem is uncertain in some cases, but probable in some (see  PRECAUTIONS  ). 
</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="17" name="heading" section="S1" start="4" />
    <IgnoredRegion len="11" name="heading" section="S2" start="4" />
    <IgnoredRegion len="8" name="heading" section="S3" start="4" />
    <IgnoredRegion len="0" name="heading" section="S3" start="19" />
    <IgnoredRegion len="10" name="heading" section="S2" start="22" />
    <IgnoredRegion len="0" name="heading" section="S3" start="668" />
    <IgnoredRegion len="0" name="heading" section="S2" start="1173" />
    <IgnoredRegion len="0" name="heading" section="S3" start="1509" />
    <IgnoredRegion len="0" name="heading" section="S3" start="1660" />
    <IgnoredRegion len="0" name="heading" section="S2" start="2238" />
    <IgnoredRegion len="0" name="heading" section="S2" start="3024" />
    <IgnoredRegion len="0" name="heading" section="S2" start="3490" />
    <IgnoredRegion len="0" name="heading" section="S2" start="4193" />
    <IgnoredRegion len="0" name="heading" section="S2" start="4713" />
    <IgnoredRegion len="0" name="heading" section="S2" start="5010" />
    <IgnoredRegion len="0" name="heading" section="S2" start="5472" />
    <IgnoredRegion len="0" name="heading" section="S2" start="6135" />
    <IgnoredRegion len="0" name="heading" section="S2" start="6452" />
    <IgnoredRegion len="0" name="heading" section="S2" start="6837" />
    <IgnoredRegion len="0" name="heading" section="S2" start="7069" />
    <IgnoredRegion len="56" name="heading" section="S2" start="7348" />
    <IgnoredRegion len="0" name="heading" section="S2" start="7822" />
    <IgnoredRegion len="0" name="heading" section="S2" start="8627" />
    <IgnoredRegion len="0" name="heading" section="S2" start="8887" />
    <IgnoredRegion len="0" name="heading" section="S2" start="8994" />
  </IgnoredRegions>
  <Mentions>
    </Mentions>
</SubmissionLabel>